Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

PURPOSE: Current therapy for lung cancer involves multimodality therapies. However, many patients are either refractory to therapy or develop drug resistance. KRAS and epidermal growth factor receptor (EGFR) mutations represent some of the most common mutations in lung cancer, and many studies have...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Girnun, Geoffrey D., Chen, Liang, Silvaggi, Jessica, Drapkin, Ronny, Chirieac, Lucian R., Padera, Robert F., Upadhyay, Rabi, Vafai, Scott B., Weissleder, Ralph, Mahmood, Umar, Naseri, Elnaz, Buckley, Stephanie, Li, Danan, Force, Jeremy, McNamara, Kate, Demetri, George, Spiegelman, Bruce M., Wong, Kwok-Kin
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2696122/
https://ncbi.nlm.nih.gov/pubmed/18927287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1128
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados